The risk of end stage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias?
- PMID: 14638360
- DOI: 10.1111/j.1572-0241.2003.07678.x
The risk of end stage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias?
Abstract
Objectives: In persons infected with hepatitis C virus (HCV), the incidence of cirrhosis and hepatocellular carcinoma (HCC) can be estimated by examining over time entire cohorts with known onset of HCV infection. We performed a systematic review of the literature to identify and to analyze studies that examine such cohorts.
Methods: A search of all articles from 1980 to 2001 was performed. Published studies were included in which chronic HCV infection was defined by elevation of liver enzymes or persistent RNA. We excluded studies in which cohorts were selected from patients with prevalent liver disease or in whom the onset of infection could not be estimated. Two investigators abstracted the data. The incidences of cirrhosis and HCC were analyzed in all studies and in categories based on study design, mode of HCV acquisition, sample size and duration of follow-up, age at the onset of infection, and the quality of estimating the onset of HCV infection.
Results: Of the articles, 21 fulfilled the selection criteria. Studies varied in sample size (17-1,680), duration of follow-up (8-45 yr), total person-years (157-34,098), and the mean age at onset of HCV (5-58 yr). The mean time to end stage liver disease (ESLD) was 4-23 yr and to HCC was 9-31 yr. A funnel plot showed a possible publication bias against studies with low incidence of ESLD and HCC. The pooled weighted incidence rates for ESLD and HCC based on infection mode were as follows: community-acquired HCV, 1.9 and 0 per 1,000 person-years; transfusion associated, 4.5 and 0.7; hemophilia patients, 7.9 and 1.0; anti-D IgG, 0.7 and 0 per 1,000 person-years. Poisson regression modeling showed that the incidence of ESLD is increased in studies with a low quality estimate of the onset of HCV infection, in community-acquired and transfusion-associated HCV, and in studies with prospective design.
Conclusions: We found large variation in the incidence estimates of cirrhosis and HCC. Short duration of follow-up, small sample size, and possible publication bias may explain some of this variation. Low quality estimates of the onset of HCV infection, a prospective study design, and a transfusion- or hemophilia-related mode of acquisition were independent predictors of high reported incidence of ESLD.
Similar articles
-
Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Co-infected Patients With Cirrhosis Are No Longer at Higher Risk for Hepatocellular Carcinoma or End-Stage Liver Disease as Compared to HCV Mono-infected Patients.Hepatology. 2019 Sep;70(3):939-954. doi: 10.1002/hep.30400. Epub 2019 Mar 15. Hepatology. 2019. PMID: 30569448
-
Risk of end-stage liver disease, hepatocellular carcinoma, and liver-related death by fibrosis stage in the hepatitis C Alaska Cohort.Hepatology. 2017 Jul;66(1):37-45. doi: 10.1002/hep.29115. Epub 2017 May 22. Hepatology. 2017. PMID: 28195349 Free PMC article.
-
Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C.Am J Gastroenterol. 2001 Jan;96(1):179-83. doi: 10.1111/j.1572-0241.2001.03374.x. Am J Gastroenterol. 2001. PMID: 11197250
-
Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis.Int J Drug Policy. 2015 Oct;26(10):911-21. doi: 10.1016/j.drugpo.2015.07.004. Epub 2015 Jul 26. Int J Drug Policy. 2015. PMID: 26298331 Free PMC article. Review.
-
Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies.Ann Intern Med. 2013 Mar 5;158(5 Pt 1):329-37. doi: 10.7326/0003-4819-158-5-201303050-00005. Ann Intern Med. 2013. PMID: 23460056 Review.
Cited by
-
FIB-4 Regression With Direct-Acting Antiviral Therapy in Patients With Hepatitis C Infection: A Safety-Net Hospital Experience.Front Med (Lausanne). 2020 Jul 22;7:359. doi: 10.3389/fmed.2020.00359. eCollection 2020. Front Med (Lausanne). 2020. PMID: 32793612 Free PMC article.
-
Reconstruction of the regulatory hypermethylation network controlling hepatocellular carcinoma development during hepatitis C viral infection.J Integr Bioinform. 2023 Nov 20;20(3):20230013. doi: 10.1515/jib-2023-0013. eCollection 2023 Sep 1. J Integr Bioinform. 2023. PMID: 37978846 Free PMC article.
-
Hepatectomy outcomes in patients with hepatitis C virus-related hepatocellular carcinoma with or without cirrhosis.Ann Surg Treat Res. 2022 Jan;102(1):1-9. doi: 10.4174/astr.2022.102.1.1. Epub 2022 Jan 3. Ann Surg Treat Res. 2022. PMID: 35071114 Free PMC article.
-
Associations of DDX60L With the Clinical Features and Prognosis of Hepatocellular Carcinoma.Front Oncol. 2022 Feb 11;12:761021. doi: 10.3389/fonc.2022.761021. eCollection 2022. Front Oncol. 2022. PMID: 35223465 Free PMC article.
-
Evidence-based clinical practice guidelines for Liver Cirrhosis 2020.J Gastroenterol. 2021 Jul;56(7):593-619. doi: 10.1007/s00535-021-01788-x. Epub 2021 Jul 7. J Gastroenterol. 2021. PMID: 34231046 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical